BioSpace News Archive

Business

Tango Therapeutics Appoints Malte Peters, MD, to Board of Directors

Tango Therapeutics today announced the appointment of Malte Peters, MD, to its board of directors.

October 10, 2018
·
2 min read
Drug Development

Alphamab Oncology’s first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial

Alphamab Oncology announced that its proprietary humanized PD-L1 - CTLA-4 bispecific antibody (product code: KN046) program, the first of its class, has recently started phase I clinical trial in Australia.

October 10, 2018
·
2 min read
Job Trends

Vizient Publishes Field Guide for Improving Care for Veterans

- In the United States there are currently about 20 million veterans, many still struggling with the wounds of war long after they’ve returned to civilian life

October 10, 2018
·
3 min read
Pharm Country

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease

October 10, 2018
·
12 min read
Drug Development

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Mayo Clinic Receives $11 Million to Study TPIV110 in Combination with Trastuzumab (Herceptin®)

October 10, 2018
·
4 min read
Business

ROSLINCT and REPROCELL Awarded £1.2 Million from Innovate UK for Clinical-Grade Stem Cell Production

Funding will be used to improve efficiency of induced pluripotent stem cell production

October 10, 2018
·
2 min read
Deals

Kodiak Sciences Inc. Announces Closing of Initial Public Offering

Kodiak Sciences Inc. today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share.

October 10, 2018
·
1 min read
Drug Development

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors

First patient dosed in Phase I clinical study to evaluate MaxCyte’s lead CAR therapeutic in ovarian cancer and peritoneal mesothelioma

October 10, 2018
·
3 min read
Drug Development

Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. is pleased to announce that it has received approval from Health Canada to initiate the first part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346.

October 10, 2018
·
3 min read
Business

Tris Pharma Announces Hiring of Chief Commercial Officer

Tris Pharma, Inc. today announced the appointment of Thomas Curatolo as Chief Commercial Officer to lead Tris’ expanded Attention Deficit Hyperactivity Disorder (ADHD) portfolio.

October 10, 2018
·
2 min read